ReviewNature reviews. Urology2026
Optimizing local control in the surgical management of bladder cancer.
Review in Nature reviews. Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery.Nature reviews. Urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a highly prevalent disease in the Western World, and the treatment paradigm is actively evolving. For decades, the most commonly used standard of care for localized muscle-invasive disease has been neoadjuvant chemotherapy followed by open radical cystectomy with urinary diversion. Considering the high postoperative morbidity of this procedure, efforts have focused on improving patient outcomes. Over the past decade, substantial advances have been introduced in imaging, prehabilitation, perioperative care, robotic surgery and organ-sparing techniques. Bladder preservation after complete clinical response to neoadjuvant treatment or after trimodal treatment is increasingly being implemented. In addition, novel biomarkers are increasingly being used to monitor treatment response and select patients for adequate therapy. Last, innovative approaches, such as intraoperative imaging, sentinel lymph-node biopsy or the use of artificial intelligence, are currently under investigation.
Indexed as
Identifiers
41168440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.